secwatch.observer — SEC 8-K summary
======================================

Issuer:     EXELIXIS, INC. (EXEL)
CIK:        0000939767
Form:       8-K
Filed at:   2024-05-20T23:59:59+00:00
Accession:  0000939767-24-000074
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Exelixis settles CABOMETYX patent litigation; Cipla generic launch from Jan 1, 2031
--------------------------------------------------------------------------------

- Settlement with Cipla resolves two Hatch-Waxman patent suits over CABOMETYX (cabozantinib).
- Cipla receives license to market generic CABOMETYX in US starting January 1, 2031, if FDA approved.
- All ongoing Delaware district court litigation will be dismissed pending FTC review.
- Agreement confidential and subject to review by FTC and DOJ.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/939767/000093976724000074/0000939767-24-000074-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/939767/000093976724000074/exel-20240520.htm
  HTML page:      https://secwatch.observer/filing/0000939767-24-000074

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer